RAIN - Dosing underway in Rain Therapeutics' mid-stage milademetan trial for advanced solid tumors

Rain Therapeutics (NASDAQ:RAIN) announces that the first patient has been dosed in the Phase 2 basket trial evaluating milademetan, an oral mouse double minute 2 (MDM2) inhibitor, for the treatment of MDM2-amplified advanced solid tumors. Approx. 65 patients are anticipated to be enrolled to receive milademetan. The primary endpoint of the trial is objective response rate as measured by RECIST criteria. Secondary endpoints include duration of response, disease control rate progression-free survival by investigator assessment, overall survival and, and growth modulation index. An interim analysis from MANTRA-2 is anticipated in H2 2022.

For further details see:

Dosing underway in Rain Therapeutics' mid-stage milademetan trial for advanced solid tumors